SINOVAC Launches "Laifu Initiative" with 69 Global Partners to Strengthen Biopharmaceutical Ecosystem Resilience

BEIJING, Aug. 29, 2025 — SINOVAC Biotech Ltd. ("SINOVAC" or the "Company"), a leading global provider of biopharmaceutical products, hosted the 2025 Supply Chain Eco-Conference at the newly inaugurated SINOVAC Laifu City campus in Beijing. During the event, SINOVAC and 69 strategic partners jointly released the Laifu Initiative, a strategic roadmap designed to catalyze innovation and strengthen the resilience of the global biopharmaceutical ecosystem.

The conference convened key executives from global industry leaders including Thermo Fisher Scientific, Danaher Corporation, Cytiva, Truking Technology, WEGO, and Cobetter. The conference focused on accelerating upstream and downstream collaboration to address evolving challenges in the global healthcare landscape.

The Four Pillars of the Laifu Initiative

1. Advancing Two-Way Openness: Encouraging global partners to participate in China's healthcare development while supporting Chinese enterprises in expanding high-quality products and services to international markets.

2. Accelerating R&D Breakthroughs: Establishing joint research platforms to overcome technical bottlenecks, share innovation outcomes, and secure a competitive edge in next-generation biopharmaceutical technologies.

3. Integrating the Full Value Chain: Transitioning from traditional procurement models to deep strategic integration across R&D, manufacturing, and quality control to enhance supply chain stability and risk resilience.

4. Commitment to Quality and Operational Excellence: Adhering to the highest global quality standards while optimizing processes and resources to achieve cost-efficiency and sustainable, multi-party growth.

In his keynote address, Mr. Yin Weidong, Chairman, President, and CEO of SINOVAC, highlighted fourtransformative trends reshaping the industry: the universal application of biotechnology, the convergence of AI and biotech, shifting geopolitical landscapes, and the role of China's 1.4-billion-person domestic market as a robust anchor for global engagement.

In the face of these four trends in the landscape, Mr. Yin believes that the true way forward for China's biopharmaceutical industry is to provide a "Global Solution" for human health meeting new health needs with the best services and scientific products, winning the trust of more countries through the highest quality standards, and ensuring vaccines are affordable and accessible to more people through maximum production volume and minimum cost.

The event featured 14 partners presenting innovations in raw materials, laboratory equipment, and quality control solutions.

Driven by innovation and global synergy, the Chinese biopharmaceutical industry has transitioned from a follower to a strategic partner on the global stage. SINOVAC remains committed to deep-level collaboration as the definitive pathway to addressing global health challenges and achieving sustainable growth.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.

The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.

SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.

Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.

With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.

For more information, please see the Company’s website at www.sinovac.com.